In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy
Boron neutron capture therapy (BNCT) requires pharmaceutical innovations and molecular-based evidence of effectiveness to become a standard cancer therapeutic in the future. Recently, in Japan, 4-borono-L-phenylalanine (BPA) was approved as a boron agent for BNCT against head and neck (H&N) canc...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/10/2149 |
| _version_ | 1827705657341509632 |
|---|---|
| author | Atsushi Fujimura Seiji Yasui Kazuyo Igawa Ai Ueda Kaori Watanabe Tadashi Hanafusa Yasuaki Ichikawa Sachiko Yoshihashi Kazuki Tsuchida Atsunori Kamiya Shuichi Furuya |
| author_facet | Atsushi Fujimura Seiji Yasui Kazuyo Igawa Ai Ueda Kaori Watanabe Tadashi Hanafusa Yasuaki Ichikawa Sachiko Yoshihashi Kazuki Tsuchida Atsunori Kamiya Shuichi Furuya |
| author_sort | Atsushi Fujimura |
| collection | DOAJ |
| description | Boron neutron capture therapy (BNCT) requires pharmaceutical innovations and molecular-based evidence of effectiveness to become a standard cancer therapeutic in the future. Recently, in Japan, 4-borono-L-phenylalanine (BPA) was approved as a boron agent for BNCT against head and neck (H&N) cancers. H&N cancer appears to be a suitable target for BPA-BNCT, because the expression levels of L-type amino acid transporter 1 (LAT1), one of the amino acid transporters responsible for BPA uptake, are elevated in most cases of H&N cancer. However, in other types of cancer including malignant brain tumors, LAT1 is not always highly expressed. To expand the possibility of BNCT for these cases, we previously developed poly-arginine peptide (polyR)-conjugated mercaptoundecahydrododecaborate (BSH). PolyR confers the cell membrane permeability and tumor selectivity of BSH. However, the molecular determinants for the properties are not fully understood. In this present study, we have identified the cluster of differentiation 44 (CD44) protein and translational machinery proteins as a major cell surface target and intracellular targets of BSH-polyR, respectively. CD44, also known as a stem cell-associated maker in various types of cancer, is required for the cellular uptake of polyR-conjugated molecules. We showed that BSH-polyR was predominantly delivered to a CD44<sup>High</sup> cell population of cancer cells. Once delivered, BSH-polyR interacted with the translational machinery components, including the initiation factors, termination factors, and poly(A)-biding protein (PABP). As a proof of principle, we performed BSH-polyR-based BNCT against glioma stem-like cells and revealed that BSH-polyR successfully induced BNCT-dependent cell death specifically in CD44<sup>High</sup> cells. Bioinformatics analysis indicated that BSH-polyR would be suitable for certain types of malignant tumors. Our results shed light on the biochemical properties of BSH-polyR, which may further contribute to the therapeutic optimization of BSH-BNCT in the future. |
| first_indexed | 2024-03-10T16:06:58Z |
| format | Article |
| id | doaj.art-b4b42b5ee5c943a486f689fb325c03e4 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T16:06:58Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-b4b42b5ee5c943a486f689fb325c03e42023-11-20T14:47:44ZengMDPI AGCells2073-44092020-09-01910214910.3390/cells9102149In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture TherapyAtsushi Fujimura0Seiji Yasui1Kazuyo Igawa2Ai Ueda3Kaori Watanabe4Tadashi Hanafusa5Yasuaki Ichikawa6Sachiko Yoshihashi7Kazuki Tsuchida8Atsunori Kamiya9Shuichi Furuya10Department of Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanNeutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanNeutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanNeutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanNeutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanNeutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanNeutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanGraduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, JapanGraduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, JapanDepartment of Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanNeutron Therapy Research Center, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanBoron neutron capture therapy (BNCT) requires pharmaceutical innovations and molecular-based evidence of effectiveness to become a standard cancer therapeutic in the future. Recently, in Japan, 4-borono-L-phenylalanine (BPA) was approved as a boron agent for BNCT against head and neck (H&N) cancers. H&N cancer appears to be a suitable target for BPA-BNCT, because the expression levels of L-type amino acid transporter 1 (LAT1), one of the amino acid transporters responsible for BPA uptake, are elevated in most cases of H&N cancer. However, in other types of cancer including malignant brain tumors, LAT1 is not always highly expressed. To expand the possibility of BNCT for these cases, we previously developed poly-arginine peptide (polyR)-conjugated mercaptoundecahydrododecaborate (BSH). PolyR confers the cell membrane permeability and tumor selectivity of BSH. However, the molecular determinants for the properties are not fully understood. In this present study, we have identified the cluster of differentiation 44 (CD44) protein and translational machinery proteins as a major cell surface target and intracellular targets of BSH-polyR, respectively. CD44, also known as a stem cell-associated maker in various types of cancer, is required for the cellular uptake of polyR-conjugated molecules. We showed that BSH-polyR was predominantly delivered to a CD44<sup>High</sup> cell population of cancer cells. Once delivered, BSH-polyR interacted with the translational machinery components, including the initiation factors, termination factors, and poly(A)-biding protein (PABP). As a proof of principle, we performed BSH-polyR-based BNCT against glioma stem-like cells and revealed that BSH-polyR successfully induced BNCT-dependent cell death specifically in CD44<sup>High</sup> cells. Bioinformatics analysis indicated that BSH-polyR would be suitable for certain types of malignant tumors. Our results shed light on the biochemical properties of BSH-polyR, which may further contribute to the therapeutic optimization of BSH-BNCT in the future.https://www.mdpi.com/2073-4409/9/10/2149boron neutron capture therapy (BNCT)BSH-polyRCD44translational machinerybioinformatics |
| spellingShingle | Atsushi Fujimura Seiji Yasui Kazuyo Igawa Ai Ueda Kaori Watanabe Tadashi Hanafusa Yasuaki Ichikawa Sachiko Yoshihashi Kazuki Tsuchida Atsunori Kamiya Shuichi Furuya In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy Cells boron neutron capture therapy (BNCT) BSH-polyR CD44 translational machinery bioinformatics |
| title | In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy |
| title_full | In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy |
| title_fullStr | In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy |
| title_full_unstemmed | In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy |
| title_short | In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy |
| title_sort | in vitro studies to define the cell surface and intracellular targets of polyarginine conjugated sodium borocaptate as a potential delivery agent for boron neutron capture therapy |
| topic | boron neutron capture therapy (BNCT) BSH-polyR CD44 translational machinery bioinformatics |
| url | https://www.mdpi.com/2073-4409/9/10/2149 |
| work_keys_str_mv | AT atsushifujimura invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT seijiyasui invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT kazuyoigawa invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT aiueda invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT kaoriwatanabe invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT tadashihanafusa invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT yasuakiichikawa invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT sachikoyoshihashi invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT kazukitsuchida invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT atsunorikamiya invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy AT shuichifuruya invitrostudiestodefinethecellsurfaceandintracellulartargetsofpolyarginineconjugatedsodiumborocaptateasapotentialdeliveryagentforboronneutroncapturetherapy |